2026 International Society of Hypertension Global Hypertension Practice Guidelines
In brief
2026 hypertension guidelines draw on 23 reviewers from 16 countries
The 2026 International Society of Hypertension guidelines are presented with a 23-member review panel spanning 16 countries. The abstract provides no details on recommended blood pressure targets, treatments, or changes from prior guidance, so clinicians will need the full guideline to see what it advises and how it may affect practice.
- Journal
- Journal of hypertension (Q1)
- Published
- 20 October 2026
- Study design
- Practice guideline / consensus
- Evidence level
- Level 1, High (CEBM 1c)
- Authors
- George S Stergiou, Kazuomi Kario, Dagnovar Aristizabal, Hind Beheiry, Myeong-Chan Cho, Débora Simões Almeida Colombari, et al.
- PMID
- 42909506
- DOI
- 10.1097/HJH.0000000000004451
Why clinicians should know about it
- Picked for Internal Medicine (paper of the day, 26 October 2026): Global hypertension practice guideline for general clinical management
Abstract
Guideline reviewers: Claudio Borghi (Italy), Fadi Charchar (Malaysia), Alfred Doku (Ghana), Maria Dorobantu (Romania), Joseph Flynn (USA), Nadia Khan (Canada), Anastasios Kollias (Greece), Reinhold Kreutz (Germany), Azra Mahmud (Pakistan), Giuseppe Mancia (Italy), Gianfranco Parati (Italy), Neil Poulter (UK), Jane Reckelhoff (USA), Nicolas Renna (Argentina), Abdulla Shehab (UAE), Markus Schlaich (Australia), Aletta Schutte (Australia), Boon Wee Teo (Singapore), Maciej Tomaszewski (UK), Rhian Touyz (Canada), Jiguang Wang (China), Thomas Weber (Austria), Paul Whelton (USA) and Yuqing Zhang (China).
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.